MX2024013673A - Metodos para tratar la enfermedad de pompe - Google Patents
Metodos para tratar la enfermedad de pompeInfo
- Publication number
- MX2024013673A MX2024013673A MX2024013673A MX2024013673A MX2024013673A MX 2024013673 A MX2024013673 A MX 2024013673A MX 2024013673 A MX2024013673 A MX 2024013673A MX 2024013673 A MX2024013673 A MX 2024013673A MX 2024013673 A MX2024013673 A MX 2024013673A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- pompe disease
- treating pompe
- treating
- population
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338601P | 2022-05-05 | 2022-05-05 | |
| US202263399498P | 2022-08-19 | 2022-08-19 | |
| US202263399491P | 2022-08-19 | 2022-08-19 | |
| US202263404475P | 2022-09-07 | 2022-09-07 | |
| US202263414897P | 2022-10-10 | 2022-10-10 | |
| US202263428970P | 2022-11-30 | 2022-11-30 | |
| US202263431920P | 2022-12-12 | 2022-12-12 | |
| US202263434791P | 2022-12-22 | 2022-12-22 | |
| US202363447222P | 2023-02-21 | 2023-02-21 | |
| PCT/US2023/066657 WO2023215865A1 (en) | 2022-05-05 | 2023-05-05 | Methods for treating pompe disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024013673A true MX2024013673A (es) | 2024-12-06 |
Family
ID=86692686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013673A MX2024013673A (es) | 2022-05-05 | 2024-11-05 | Metodos para tratar la enfermedad de pompe |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20260041744A1 (enExample) |
| EP (1) | EP4518885A1 (enExample) |
| JP (1) | JP2025515159A (enExample) |
| KR (1) | KR20250007602A (enExample) |
| CN (1) | CN119343147A (enExample) |
| AU (1) | AU2023265155A1 (enExample) |
| CA (1) | CA3252291A1 (enExample) |
| CL (1) | CL2024003377A1 (enExample) |
| CO (1) | CO2024016724A2 (enExample) |
| IL (1) | IL316776A (enExample) |
| MX (1) | MX2024013673A (enExample) |
| TW (1) | TW202400212A (enExample) |
| WO (1) | WO2023215865A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026006625A1 (en) | 2024-06-26 | 2026-01-02 | Amicus Therapeutics, Inc. | Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| WO2009102895A2 (en) | 2008-02-12 | 2009-08-20 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| US11382980B2 (en) | 2013-10-08 | 2022-07-12 | Taiyo Kagaku Co., Ltd. | Oil/fat composition containing polyunsaturated fatty acid |
| JP6851964B2 (ja) * | 2014-09-30 | 2021-03-31 | アミカス セラピューティックス インコーポレイテッド | 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ |
| IL299470B2 (en) * | 2015-12-30 | 2026-05-01 | Amicus Therapeutics Inc | Improved acid alpha-glucosidase for the treatment of Pompe disease |
| CA3019354A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| KR102618519B1 (ko) * | 2016-03-30 | 2023-12-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| CN119113091A (zh) * | 2017-05-15 | 2024-12-13 | 阿米库斯治疗学公司 | 重组人类酸性α-葡萄糖苷酶 |
| WO2020163480A1 (en) | 2019-02-05 | 2020-08-13 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase and uses thereof |
| JP2024506346A (ja) * | 2021-02-11 | 2024-02-13 | アミカス セラピューティックス インコーポレイテッド | 組換えヒト酸性アルファグルコシダーゼ及びその使用 |
-
2023
- 2023-05-05 WO PCT/US2023/066657 patent/WO2023215865A1/en not_active Ceased
- 2023-05-05 KR KR1020247039256A patent/KR20250007602A/ko active Pending
- 2023-05-05 AU AU2023265155A patent/AU2023265155A1/en active Pending
- 2023-05-05 CA CA3252291A patent/CA3252291A1/en active Pending
- 2023-05-05 EP EP23728984.8A patent/EP4518885A1/en active Pending
- 2023-05-05 TW TW112116800A patent/TW202400212A/zh unknown
- 2023-05-05 JP JP2024565157A patent/JP2025515159A/ja active Pending
- 2023-05-05 CN CN202380045183.6A patent/CN119343147A/zh active Pending
- 2023-05-05 IL IL316776A patent/IL316776A/en unknown
- 2023-05-05 US US18/863,111 patent/US20260041744A1/en active Pending
-
2024
- 2024-11-05 MX MX2024013673A patent/MX2024013673A/es unknown
- 2024-11-05 CL CL2024003377A patent/CL2024003377A1/es unknown
- 2024-12-05 CO CONC2024/0016724A patent/CO2024016724A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL316776A (en) | 2025-01-01 |
| CN119343147A (zh) | 2025-01-21 |
| CA3252291A1 (en) | 2023-11-09 |
| AU2023265155A1 (en) | 2024-12-12 |
| KR20250007602A (ko) | 2025-01-14 |
| WO2023215865A1 (en) | 2023-11-09 |
| CL2024003377A1 (es) | 2025-03-28 |
| US20260041744A1 (en) | 2026-02-12 |
| CO2024016724A2 (es) | 2025-04-28 |
| JP2025515159A (ja) | 2025-05-13 |
| EP4518885A1 (en) | 2025-03-12 |
| TW202400212A (zh) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023011696A (ja) | 核酸産物およびその投与方法 | |
| EP2337790B1 (en) | Clostridial neurotoxins with altered persistency | |
| BR112013030432A2 (pt) | método para preparar um peptídeo conjugado alvo para uma enzima lisossomal recombinante, método para preparar uma molécula para terapia de reposição de enzima, conjugado, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um indivíduo sofrendo de uma doença de armazenamento lisossomal, método para tratar um paciente sofrendo da doença de pompe, doença de fabry, e doença de gaucher, mps i, mps ii, mps vii, tay sachs, sandhoff, alfa-manosidose, e wohlman, sequência de dna e sequência de aminoácidos | |
| TW202247855A (zh) | 非蛋白梭菌毒素組成物 | |
| BR112023016212A2 (pt) | Alfa-glucosidase ácida humana recombinante e usos da mesma | |
| JP7162059B2 (ja) | 自律神経障害の治療 | |
| MX2025006410A (es) | Fexamétodos para tratar la enfermedad de pompe de inicio infantil en pacientes pediátricos | |
| BR112023001121A2 (pt) | Cepa c de prevotella histicola como uma terapia oral para doenças inflamatórias | |
| EP4552693A3 (en) | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | |
| WO2023070082A3 (en) | Rnai agents for inhibiting expression of matrix metalloproteinase 7(mmp7), compositions thereof, and methods of use | |
| JOP20240081A1 (ar) | مُعدِّلات الجزيئات الصغيرة لنشاط الجلوكوسيريبروسيد واستخداماتها | |
| WO2023150493A3 (en) | Cell therapy for diabetes | |
| CO2024016724A2 (es) | Métodos para tratar la enfermedad de pompe | |
| MX2025006409A (es) | Métodos para tratar la enfermedad de pompe de inicio tardío en pacientes pediátricos | |
| BRPI0416434A (pt) | métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina | |
| BR112022014119A2 (pt) | Administração oral de peptídeos | |
| BR112022012918A2 (pt) | Variantes de enzima de exaustão de metiltioadenosina/adenosina humana melhorada para terapia do câncer | |
| ES2374619T3 (es) | Uso de hialuronidasa para la profilaxis y el tratamiento de enfermedades cardiovasculares. | |
| JP6578323B2 (ja) | フィラグリン産生促進剤 | |
| US20250018016A1 (en) | Botulinum neurotoxin composition | |
| WO2024182608A3 (en) | Chemogenetics-based therapy for neurological disorders | |
| AR131257A1 (es) | Métodos para tratar la enfermedad de pompe de inicio infantil en pacientes pediátricos | |
| BR112022025314A2 (pt) | Composições e métodos para tratamento de doença de pompe de início tardio | |
| WO2021216755A9 (en) | Compositions and methods for intranasal treatment with double stranded rna | |
| WO2025059390A3 (en) | Engineered interferon-beta proteins |